Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Rockwell Medical, Inc. focuses on developing and commercializing innovative therapies for patients with end-stage renal disease (ESRD) and chronic kidney disease (CKD). Its flagship product, Triferic, is designed to maintain hemoglobin levels in patients undergoing dialysis, which sets it apart in a competitive market dominated by larger pharmaceutical firms. The company primarily operates in the United States, with a growing presence in international markets.
Rockwell Medical generates revenue primarily through the sale of its proprietary drug Triferic, which is administered to dialysis patients to manage iron levels and hemoglobin. The company benefits from a unique position in the dialysis market due to the lack of direct competition for Triferic, which offers a differentiated value proposition compared to traditional iron supplements.
Regulatory approvals for new indications of Triferic
Changes in dialysis treatment guidelines impacting product adoption
Partnerships or collaborations with larger pharmaceutical companies
Market penetration rates in both domestic and international markets
Regulatory changes affecting drug approval processes
Technological advancements in dialysis treatment that could render Triferic less competitive
Emergence of new therapies for anemia management in dialysis patients
Pricing pressures from larger competitors with more extensive product portfolios
Negative operating cash flow impacting liquidity
Potential for increased debt levels if cash burn continues
moderate - The demand for dialysis treatments is relatively inelastic, but economic downturns can impact healthcare spending and patient access.
Higher interest rates could increase the company's financing costs, impacting its ability to fund R&D and operational expenses, which may lead to a lower valuation multiple.
minimal - The company maintains a manageable debt-to-equity ratio of 0.40, indicating limited reliance on external financing.
growth - Investors looking for exposure to innovative healthcare solutions with potential for high returns.
high - The stock has exhibited significant price fluctuations, evidenced by a 46.4% decline over the past year.
